Mertansine-13C-d3
(Synonyms: DM1-13C-d3; Emtansine-13C-d3) 目录号 : GC92691Mertansine-13C-d3 is intended for use as an internal standard for the quantification of mertansine by GC- or LC-MS.
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Mertansine-13C-d3 is intended for use as an internal standard for the quantification of mertansine by GC- or LC-MS. Mertansine is a synthetic maytansinoid antimitotic agent. It is cytotoxic to KB epidermoid carcinoma and SK-BR-3 breast cancer cells (IC50 = 1.1 nM for both). Mertansine has commonly been used as a payload in antibody-drug conjugates (ADCs) that selectively target cancer cells in vitro and in animal models. Formulations containing mertansine conjugated to ado-trastuzumab have been used in the treatment of HER2+ breast cancer.
| Cas No. | SDF | ||
| 别名 | DM1-13C-d3; Emtansine-13C-d3 | ||
| 化学名 | (14S,16S,32S,33S,2R,4S,10E,12E,14R)-86-chloro-14-hydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-12,6-dioxo-7-aza-1(6,4)-oxazinana-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-4-yl N-(3-mercaptopropanoyl)-N-(methyl-13C-d3)-L-alaninate | ||
| Canonical SMILES | C[C@@]1([C@@H](O1)[C@H](C)[C@]([H])(C[C@](N2)(O)[C@H](OC)/C=C/C=C(CC3=CC(OC)=C(Cl)C4=C3)\C)OC2=O)[C@@]([H])(OC([C@@H](N([13C]([2H])([2H])[2H])C(CCS)=O)C)=O)CC(N4C)=O | ||
| 分子式 | C34[13C]H45D3ClN3O10S | 分子量 | 742.3 |
| 溶解度 | Chloroform: Slightly soluble; Methanol: Slightly soluble | 储存条件 | -20°C |
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.3472 mL | 6.7358 mL | 13.4716 mL |
| 5 mM | 269.4 μL | 1.3472 mL | 2.6943 mL |
| 10 mM | 134.7 μL | 673.6 μL | 1.3472 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet